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Abstract: Approximately 4000 children and adolescents under the age of 20 years develop 
acute leukemia per year in the US. Acute lymphoblastic leukemia (ALL) is the most common 
pediatric cancer. Despite impressive improvements in outcome, relapsed ALL is the fourth 
most common pediatric malignancy. Therapy for relapsed ALL remains unsatisfactory, and 
the majority of relapse patients still succumb to leukemia. Between one-third and one-half of 
patients with acute myelogenous leukemia (AML) relapse, and no standard therapy is recog-
nized for patients with relapsed and/or refractory AML. Novel therapeutic agents are needed to 
improve the cure rate for relapsed ALL and AML. Clofarabine is a next-generation nucleoside 
analog, designed to incorporate the best features and improve the therapeutic index of cladrib-
ine and ﬂ  udarabine. Clofarabine inhibits both DNA polymerase and ribonucleotide reductase, 
leading to impaired DNA synthesis and repair, and directly induces apoptosis. Phase I and II 
single-agent trials in children have shown that clofarabine is safe and active in both myeloid 
and lymphoid relapsed/refractory acute leukemias. Clofarabine has been approved by the FDA 
for pediatric patients with relapsed/refractory ALL after at least 2 prior therapeutic attempts. 
Rational combinations of clofarabine with other active agents in refractory leukemias are cur-
rently under investigation.
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Introduction
Approximately 4000 children and adolescents under the age of 20 years develop acute 
leukemia per year in the US. Acute lymphoblastic leukemia (ALL) is the most common 
pediatric cancer, accounting for one-fourth of all childhood cancers and approximately 
75% of all cases of childhood leukemia. In the US alone, approximately 3000 cases 
of pediatric ALL are diagnosed annually, with an incidence of 29.2 cases per million 
per year (Grovas et al 1997; Jemal et al 2004).
Primary treatment of pediatric ALL is “risk-adapted,” ie, treatment allocation is 
based on an estimate of risk of relapse based on presenting features, eg, age at diagnosis, 
initial white blood cell count, immunophenotype, and cytogenetics and response to 
therapy, eg, disappearance of peripheral blasts, microscopic marrow response, and/or 
laboratory measurement submicroscopic leukemia, termed minimal residual disease 
(MRD) (Schultz et al 2007). Increasingly effective post induction intensiﬁ  cation 
employing conventional agents has steadily improved event-free survival. According 
to the US population-based Surveillance and End Results survey, 5-year survival for 
children aged 1–14 years has increased from 53% in 1974–76 to 85% in 1992–1999 
(Jemal et al 2004).
Despite the impressive improvements in outcome, relapsed ALL remains the 
fourth most common pediatric malignancy, with an incidence of approximately 
6 cases per million in 2007 (Gaynon et al 1998). Therapy for patients with relapsed 
ALL remains unsatisfactory, especially for patients with early bone marrow relapse Therapeutics and Clinical Risk Management 2008:4(2) 328
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within 3 years of diagnosis (Gaynon et al 1998; Nguyen et al 
2006). Second remissions are common. Four-drug therapy 
with vincristine, prednisone, asparaginase, and doxorubicin 
induces complete remissions in 38%, 80%, and 95% of 
children with initial remissions  18 months, 18–36 months, 
and  36 months, respectively. Of patients achieving CR2, 
80% remain MRD positive at 10–4 by ﬂ  ow cytometry after 
CR1   36 months compared to 50% positive for CR1   36 
months (Raetz et al 2006). Therapeutic options after second 
remission (CR2) include further chemotherapy and/or hema-
topoietic stem cell transplantation (HSCT) (Eapen et al 2006; 
Gaynon et al 2006).
However, the majority of relapse patients still succumb 
to leukemia. For patients enrolled on Children’s Cancer 
Group (CCG) 1900 series studies between 1997 and 2002, 
the 3-year survival after marrow, CNS, and testes relapse 
was 28%, 60%, and 60%, respectively (Nguyen et al 2006). 
Adverse prognostic factors after relapse include early ver-
sus late timing, marrow versus extramedullary relapse, and 
T-cell versus B-precursor immunophenotype (Chessells 
1998; Eckert et al 2001; Chessells et al 2003; Einsiedel et al 
2005). MRD after re-induction chemotherapy, as measured 
by PCR or ﬂ  ow cytometry, may be predictive of outcome in 
CR2 after marrow relapse (Eckert et al 2001; Coustan-Smith 
et al 2004). Higher levels of pre-transplant MRD may predict 
relapse after hematopoietic stem cell transplant (HSCT) 
(Knechtli et al 1998; Bader et al 2002; Goulden et al 2003). 
Better pre-transplant chemotherapy is needed that allows 
more patients to proceed to transplant with lower MRD and 
less deep seated infection or organ damage.
Although third remissions are attained with some fre-
quency, outcomes for patients with second or subsequent 
relapse remain poor (Chessells 1998; Chessells et al 2003). 
Several drug combinations have signiﬁ  cant CR rates in 
refractory ﬁ  rst relapse, or second or subsequent relapse 
(Table 1). These CR rates cluster around 40%, despite the 
use of a variety of drugs with different putative mechanisms 
of action (Gaynon 2005). An overall 8% survival rate was 
reported among patients who achieved third remission after 
a second marrow relapse (Chessells et al 2003).
We have proposed that candidate drug combinations with 
CR rates  40% are unlikely to be useful for improving cure 
rates. Alternatively, novel regimens with CR rates  60% 
would be of compelling interest (Gaynon 2005). Although 
data are lacking for CR3 and subsequent remissions, mea-
surement of minimal residual disease (MRD) may be useful 
to assess response.
Acute myelogenous leukemia (AML) comprises 15%–20% 
of childhood leukemia, but accounts for more than 30% 
of deaths from leukemia. In the US, approximately 1000 
children per year are diagnosed with AML, with an incidence 
of between 5 and 7 cases per million per year (Grovas et al 
1997; Jemal et al 2004). Better supportive care and better use 
of conventional agents have improved outcomes in childhood 
AML. Current therapy for patients with newly diagnosed AML 
involves induction therapy with myelosuppressive cytotoxic 
agents, including cytarabine and an anthracycline or anthracin-
edione, and post-remission intensiﬁ  cation with chemotherapy 
or HSCT. Three recent large multi-center pediatric studies 
yielded remission induction rates of approximately 90%. 
Five-year event-free survival is nearing or surpassing 50% 
(Aladjidi et al 2003; Creutzig et al 2005, 2006; Gibson et al 
2005). Risk-group stratiﬁ  cation based on cytogenetic features, 
FLT-3 expression (Pollard et al 2006), and response to therapy 
is becoming increasingly important.
One-third to one-half of patients with AML relapse. Most 
relapses are isolated to the bone marrow, and are more likely 
to occur in the ﬁ  rst year after diagnosis. No standard therapy 
is recognized for patients with relapsed and/or refractory 
AML. Regimens that contain high-dose cytarabine, often in 
combination with other agents such as mitoxantrone, etoposide, 
fludarabine, or 2-chlorodeoxyadenosine, have significant 
activity (Golub et al 2006). Gemtuzamab ozogamicin, a 
monoclonal antibody directed against the CD33 differentiation 
antigen and coupled to genotoxic calicheamicin, has shown 
activity in relapsed and refractory AML in both children and 
adults (Sievers et al 2001; Zwaan et al 2003; Reinhardt et al 
2004; Arceci et al 2005). Gemtuzamab is currently being 
studied in newly diagnosed children and adults in combination 
with multiagent chemotherapy (Burnett et al 2006).
Perhaps 50% of patients with primary induction failure 
will achieve CR with subsequent therapy (Wells et al 2003) 
and 70% of patients with CR1 achieve a second remission 
employing similar drugs to those used initially (Webb 1999; 
Table 1 Complete response rates in second and subsequent 
relapse ALL
Regimen  CR rate (%)  Reference
POG 8866 vincristine,  30/74 (41)  Kurtzberg et al1993
Prednisone, L-asparaginase 
POG 9160 idarubicin,cytarabine  30/82 (37)  Bernstein et al 1997
High-dose cytarabine,  22/52 (42)  Harris et al 1998
L-asparaginase
Ifosfamide, etoposide  8/20 (40)  Crooks and Sato 1995
Topotecan, vinorelbine, thiotepa,  6/17 (35)  Kolb and Steinherz
Dexamethasone and gemcitabine    2003
Derived from Gaynon 2005.
Abbreviations: ALL, acute lymphoblastic leukemia.Therapeutics and Clinical Risk Management 2008:4(2) 329
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Aladjidi et al 2003; Wells et al 2003). However, long-term 
survival for children with relapsed AML ranges between 
20% and 33% (Aladjidi et al 2003; Castellino et al 2007). 
Prognosis is related to speciﬁ  c cytogenetic abnormalities 
and the duration of ﬁ  rst remission. Patients relapsing after 
a CR1   1 year have a better survival. The need remains 
for therapeutic options which are both less toxic and more 
effective than the conventional treatment.
New agents for relapsed
and refractory childhood leukemias
Novel therapeutic agents are needed to improve the cure 
rate of patients with relapsed or refractory ALL and AML. 
Emerging new treatments for ALL include next generation 
nucleoside analogs such as the deoxyadenosine analog 
clofarabine (Clolar®, Genzyme), which was approved by 
the FDA in December 2004 for the treatment of pediatric 
patients with relapsed or refractory ALL who have received 
at least two prior chemotherapy regimens (Pui and Jeha 
2005), and the deoxyguanosine analog nelarabine (Arranon®, 
GlaxoSmithKline), which has been approved by the FDA 
for third-line treatment of patients with T-cell leukemia 
or lymphoma (Kurtzberg 2007). In acute promyelocytic 
leukemic, arsenic trioxide has shown beneﬁ  t in randomized 
trials (Powell et al 2006, 2007). In AML, preliminary data 
suggest an EFS advantage for addition of gemtuzumab to 
conventional induction chemotherapy (Burnett et al 2006) 
and an induction rate advantage for addition of the FLT-3 
inhibitor lestaurtinib for patients with AML with FLT-3 
internal tandem repeats (Levis et al 2005) . Other promising 
new agents include monoclonal antibodies against leukemia-
speciﬁ  c antigens, such as rituximab, a humanized anti-CD20 
antibody, and epratuzamab, targeting CD22.
Over 100 gene mutations and genetic abnormalities 
have been reported in AML, reﬂ  ecting the heterogeneity 
of the disease and the presence of multiple active pathways 
(Tallman 2006). Mutations that activate signal transduction 
pathways lead to proliferative survival advantages and may 
be targeted with small molecule inhibitors of the speciﬁ  c 
mutations, such as FLT3, C-Kit, and RAS, while mutations 
that lead to inhibition of differentiation may be targeted with 
differentiating agents (eg, all-trans-retinoic acid [ATRA] 
for patients with acute promyelocytic leukemia [APL]). 
Targeted therapy may interfere with host support for the 
leukemia cell. The mechanisms of treatment failure in ALL 
remain to be elucidated. One does well to remember that 
neither ATRA alone nor imatinib alone is curative for APL 
or chronic myelogenous leukemia, respectively. A gene may 
be over-expressed, yet not critically necessary for leukemic 
de-differentiation or proliferation.
New agents have been developed for multiple molecular 
targets in AML, including antibodies to cell surface antigen 
CD33, inhibitors of multi-drug resistance proteins, farnesyl 
transferase inhibitors, FLT3-targeted tyrosine kinase inhibi-
tors, and inhibitors of the antiapoptotic protein Bcl-2 and 
the mammalian target of rapamycin (mTOR). New alkyl-
ating agents and purine analogs such as cloretazine and 
clofarabine, which target DNA and ribonucleotide reduc-
tases, respectively, are also under investigation. Targeted 
agents will likely need to be used in combination with other 
targeted agents and/or cytotoxic agents to inhibit the multiple 
pathways present in AML and to improve response rates 
(Tallman 2006). Clinical beneﬁ  t will require the right stuff, 
ie, the right drug be used against the right target in the right 
disease at the right dose and schedule in the right population 
with the right accompanying therapy (Gaynon 2005). Clinical 
development of these therapies is challenging in view of the 
multitude of intriguing possibilities, the background hetero-
geneity of leukemias, and the current absence of compelling 
preclinical models (Schein 2001).
Clofarabine
The nucleoside analog family includes the guanosine analogs, 
thioguanine and mercaptopurine, which were among the ﬁ  rst 
agents to show activity against ALL (Hitchings et al 1950; 
Elion et al 1951; Skipper et al 1954). The clinical use of 
the deoxyadenosine analogs cladribine and ﬂ  udarabine 
has been restricted due to dose-limiting neurotoxicity 
(Kantarjian et al 2007). Clofarabine (2-chloro-2'-ﬂ  uoro-
2'deoxy-9-B-D-arabinofuranosyladenine), a next-generation 
deoxyadenosine analog (see Figure 1), was rationally 
designed to incorporate the best qualities and improve the 
therapeutic index of cladribine and ﬂ  udarabine. The drug 
received accelerated approval by the FDA in December 2004 
and EMEA approval in 2006 for the treatment of patients 
with childhood ALL who have received two or more prior 
therapeutic regimens.
Clofarabine retains the 2-halogenated aglycone of the 
deoxyadenoside analogs cladribine and ﬂ  udarabine (Figure 1), 
which confers resistance to cellular degradation by adenosine 
deaminase (Parker et al 1991, 1999; Pui et al 2005). However, 
clofarabine also possesses a second halogen atom (ﬂ  uorine) 
at the 2' carbon in the arabino conﬁ  guration, which inhibits 
cleavage of the glycosidic bond by bacterial purine nucleoside 
phosphorylase and stabilizes the compound in acidic environ-
ments, thus improving oral bioavailability and preventing the Therapeutics and Clinical Risk Management 2008:4(2) 330
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release of the neurotoxic halogenated adenine (Parker et al 
1991; Carson et al 1992; Plunkett and Gandhi 2001; Jeha et al 
2004; Jeha and Kantarjian 2007; Kantarjian et al 2007). In 
addition, clofarabine has greater afﬁ  nity than cladribine or 
ﬂ  udarabine for deoxycytidine kinase, the enzyme required for 
intracellular phosporylation to its monophosphorylated form. 
Clofarabine is then serially phosphorylated by other kinases 
to its active metabolite, clofarabine triphosphate (Bonate et al 
2004, 2005). Clofarabine triphosphate is retained in acute 
leukemia cells for longer periods of time than the metabolites 
of the other purine nucleoside analogs (Xie and Plunkett 1995, 
1996; Bonate et al 2006; Gandhi et al 2006,).
Mechanism of action
Purine analog triphosphates inhibit ribonucleotide reductase 
and are substrates for DNA polymerases for incorpora-
tion into DNA (Gandhi et al 2006). Fludarabine primarily 
inhibits DNA polymerases and cladribine mainly inhibits 
ribonucleotide reductase, while clofarabine inhibits both 
DNA polymerases and ribonucleotide reductase (Parker 
et al 1991, 1999; Xie and Plunkett 1995, 1996; Jeha et al 
2004). Inhibition of DNA polymerases leads to impairment 
of DNA synthesis and/or repair through the incorporation 
of clofarabine monophosphate into the DNA chain (Xie and 
Plunkett 1996; Bonate et al 2006). Inhibition of ribonucleo-
tide reductase depletes the deoxynucleotide pool primarily 
of dCTP and dATP (Xie and Plunkett 1996; Bonate et al 
2006). The reduction in dCTP concentrations limits DNA 
synthesis, while the reduction in dATP creates a favorable 
environment for clofarabine triphosphate to compete with 
dATP for incorporation into DNA (Xie and Plunkett 1996; 
Bonate et al 2006). A third mechanism of action is induc-
tion of apoptosis initiated by DNA strand breaks, resulting 
in the release of cytochrome c and activation of apoptotic 
pathways (Genini et al 2000; Bonate et al 2006). Clofarabine 
has also been shown to act directly on the mitochondria in 
primary chronic lymphocytic leukemia (CLL) cells, altering 
the transmembrane potential and releasing pro-apoptotic 
mitochondrial factors, which may explain the mechanism 
of cell death in cells not actively synthesizing DNA for cell 
division or DNA repair. This direct mitochondrial activity 
was not seen with ﬂ  udarabine and may partly explain the 
enhanced cytotoxicity of clofarabine (Carson et al 1992; 
Genini et al 2000; Bonate et al 2006).
Pharmacodynamics
In the blast cells of adults with refractory leukemias, the accu-
mulation of clofarabine triphosphate was associated with a 
decrease in DNA synthesis (Gandhi et al 2003). DNA synthesis 
was 75% to 95% inhibited at the end of an infusion with clo-
farabine at doses ranging from 22.5 to 55 mg/m2. At 24 hours, 
partial recovery of DNA synthesis occurred in the blasts of 
patients treated with 22.5 and 30 mg/m2, while the inhibition of 
DNA synthesis was maintained at 24 hours after 40–55 mg/m2 
doses (Gandhi et al 2003; Kantarjian et al 2007).
Pharmocokinetics and metabolism 
(Table 2)
The population pharmacokinetics of plasma clofarabine 
and intracellular clofarabine triphosphate was studied in 
Figure 1 Structures of clofarabine and other nucleoside analogs. Derived from Jeha et al (2004).Therapeutics and Clinical Risk Management 2008:4(2) 331
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40 pediatric patients aged 2–9 years (21 males/19 females) 
with relapsed or refractory ALL or AML. Clofarabine 
pharmacokinetics was weight dependent, suggesting the 
importance of dosing on a body surface area (BSA) basis, 
although similar concentrations were obtained over a wide 
range of BSAs at the given 52 mg/m2 dose (Bonate et al 
2004). Clofarabine was 47% bound to plasma proteins, 
mainly albumin. Systemic clearance and volume of distri-
bution at steady state were estimated to be 28.8 L/h/m2 and 
172 L/m2, respectively. The terminal half-life was estimated 
to be 5.2 hours (Bonate et al 2004). The half-life of the active 
clofarabine triphosphate metabolite could not be adequately 
characterized in the pediatric phase 2 studies but was esti-
mated to be greater than 24 hours (Bonate et al 2004). It is 
believed that the conversion from the monophosphate to the 
diphosphate moiety is the rate-limiting step in the formation 
of the triphosphate. It appears that clofarabine triphosphate 
formation is very rapid, and once formed, it remains trapped 
in the cell with a prolonged elimination half-life (Xie and 
Plunkett 1995; Bonate et al 2004). In pediatric patients 
49%–60% of the clofarabine dose is excreted unchanged 
in the urine. The pathways of non-renal elimination remain 
unknown (Gandhi et al 2003; Bonate et al 2004). Clofarabine 
does not appear to be metabolized by the cytochrome P450 
enzymes and CYP450 inhibitors and inducers are not likely 
to affect the metabolism of clofarabine, although no clinical 
drug-drug interaction studies have been conducted to date 
(Clolar® package insert).
Special populations
Clofarabine pharmacokinetics is similar in patients with ALL 
and AML or in males and females. The pharmacokinetics 
of clofarabine remains to be evaluated in patients with renal 
or hepatic dysfunction (Bonate et al 2004). According to 
the manufacturer, its use in patients with hepatic or renal 
dysfunction should be undertaken only with the greatest 
caution.
Clofarabine was found to be teratogenic in reproductive 
studies conducted in rats and rabbits, with reduced fetal 
body weight, increased fetal loss, and skeletal malformations 
observed. Therefore, although there are no adequate studies 
in pregnant women using clofarabine, women of childbearing 
potential should be advised to avoid becoming pregnant while 
receiving treatment with clofarabine (Clolar® package insert).
Efﬁ  cacy studies
Phase I studies in pediatrics
Based on a 16% overall response rate seen in adults with leu-
kemia in a phase I single-agent trial of clofarabine (Gandhi et al 
2003; Kantarjian et al 2003b; Faderl et al 2005a), a pediatric 
phase I trial was conducted to deﬁ  ne the dose-limiting toxicity 
(DLT) and maxinimu tolerated dose (MTD) for children with 
acute leukemia (Jeha et al 2004). Six dose levels, ranging from 
11.25 to 70 mg/m2 for 5 days, were studied in 25 pediatric 
patients (8 patients with AML and 17 patients with ALL). 
Most patients were heavily pretreated, with 36% having 
undergone prior stem cell transplantation (Jeha et al 2004). 
Hyperbilirubinemia and skin rash were dose-limiting and the 
recommended dose schedule for the phase 2 pediatric studies was 
52 mg/m2 daily for 5 days. Complete response (CR) was reported 
in 4 (24%) of 17 patients with ALL (Table 3). One patient 
(6%) had a partial response (PR), for an overall response rate 
(CR + PR) for ALL of 30%. Complete responses were seen 
at 30 mg/m2, 40 mg/m2, and 52 mg/m2 (Jeha et al 2004). Respond-
ers included a 13-year-old female with t(9,22) refractory to 
3 consecutive induction attempts including idarubicin, ﬂ  udara-
bine, and cytarabine, as well as a 17-year-old female with T-cell 
ALL refractory to 3 consecutive inductions including nelarabine 
(Jeha et al 2004). The overall response rate for patients with AML 
was 38% (Table 3). One out of 8 patients (13%) achieved CR 
and 2 patients (25%) achieved PR (Jeha et al 2004).
Phase II studies in children with acute 
leukemia
A phase II, open-label, multicenter clofarabine study was 
conducted in 61 pediatric patients in the US with refractory 
Table 2 Pharmacokinetics of clofarabine
Variable Value
Volume of distribution (L/m2) 172
Protein binding (%)  47
Terminal half-life (hours)  5.2
Elimination via  urine  (49%–60%)
Systemic clearance (L/h/m2) 28.8
Metabolism  Phosphorylated by deoxycytidine
  kinase phosphorylated to active
  metabolite clofarabine triphosphate
Derived from data of Bonate et al 2004.
Table 3 Response to clofarabine in phase I trials
 Responses/Total  (%)
Response ALL  AML  Total
CR  4/17 (24%)  1/8 (13%)  5/25 (20%)
PR  1/17 (6%)  2/8 (25%)  3/25 (12%)
CR + PR  5/17 (30%)  3/8 (38%)  8/25 (32%)
Derived from data of Jeha et al (2004).
Abbreviations: CR, complete response; PR, partial response.Therapeutics and Clinical Risk Management 2008:4(2) 332
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or relapsed ALL at 52 mg/m2 for 5 days (Jeha et al 2006b). 
Patients were heavily pretreated, with a median of 3 prior 
induction regimens. Approximately one-third had received 
at least 1 prior transplantion, and 57% were refractory to 
the last therapeutic regimen. Twelve of 61 ALL patients 
achieved complete remission (CR) or complete remission 
without platelet recovery (CRp). Only 1 of 42 AML patients 
achieved CRp. Of those who were refractory to their most 
recent prior regimen, the overall response rate was 17%. 
There were an additional 10% of patients who achieved a 
partial response (PR). The median duration of response for 
patients with ALL who achieved at least a partial response 
was 9.7 weeks. Responses were observed in patients with 
both B-and T-lineage ALL, and in patients with various cyto-
genetic abnormalities. Nine of the 61 ALL patients proceeded 
to HSCT, with no apparent increase in transplantation-related 
toxicity. The median duration of CR was 7 months in patients 
receiving transplants (Jeha et al 2006b; Jeha and Kantarjian 
2007). The most common adverse events, grade 3 or higher, 
were fever with neutropenia, anorexia, hypotension, and 
nausea. Similar response rates were seen in a European phase 
II trial in pediatric patients with ALL, with a reported CR + 
CRp rate of 28% (Kearns et al 2006).
Forty-two children with AML were reported in a separate 
pediatric phase II clofarabine trial. The overall response rate 
in the heavily pretreated pediatrics was 26% (1 CRp and 
8 PRs) (Table 4). The median duration of remission was 
16.2 weeks and reported toxicities were similar to patients 
with ALL (Jeha et al 2006b).
Combination studies
The pediatric phase I and phase II single agent trials deter-
mined that clofarabine was active in pediatric patient with 
relapsed and refractory ALL with an acceptable toxicity 
proﬁ  le. Rational combinations of clofarabine with other 
agents are being investigated in order to optimize clinical 
beneﬁ  t. In vitro data suggest that clofarabine, an inhibitor of 
DNA repair, may enhance the cytotoxicity of DNA-damaging 
agents such as cyclophosphamide (Yamauchi et al 2001). The 
combination of cyclophosphamide and etoposide is utilized 
during consolidation therapy for pediatric ALL patients with 
ALL in ﬁ  rst relapse (Children’s Oncology Group Protocol 
AALL01P2), and a similar ifosfamide/etoposide combina-
tion is active in multiply relapsed ALL (Crooks and Sato 
1995). A pilot phase I study of clofarabine used in combi-
nation with cyclophosphamide and etoposide is ongoing to 
determine the MTD and the dose-limiting toxicities of the 
combination. Once etoposide and cyclophosphamide were 
escalated to their target doses (100 mg/m2/day and 440 mg/
m2/day, respectively in cohort 3), clofarabine was increased 
to 30 mg/m2/day in cohort 4 and would be increased 
to 40 mg/m2 in cohort 5 (Hijiya et al 2007). To date, 19 
patients (15 ALL, 4 AML) have been enrolled in the ﬁ  rst 
4 dose cohorts (Table 5). Seventeen patients (14 ALL, 
3 AML) have response data available. The median number 
of prior regimens was 2. Seven of 14 evaluable ALL patients 
achieved a CR and 2 ALL patients achieved a CRp, for an 
overall response rate of 64% among pediatric patients with 
ALL. Three out of 3 patients with AML achieved a CRp. One 
patient in cohort 4 experienced a grade 3 elevation of lipase 
and possible veno-occlusive disease. Febrile neutropenia was 
a common toxicity. Phase 2 studies of this combination will 
take place once the MTD is determined (Hijiya et al 2007).
Other studies are investigating whether clofarabine, a 
potent inhibitor of ribonucleotide reductase, will modulate 
intracellular cytarabine (Ara-c) triphosphate accumula-
tion and increase the cytotoxicity of Ara-c (Cooper et al 
2005; Faderl et al 2005b, 2006). A phase 1–2 adult study 
in 32 adults with relapsed and refractory acute leukemias 
demonstrated that the combination of clofarabine at the 
adult MTD dose level of 40 mg/m2/day for 5 days (days 2–6) 
followed 4 hours later by cytarabine 1 g/m2 administered 
as a 2-hour intravenous infusion for 5 days (days 1–5) was 
safe and effective (Faderl et al 2005b). The overall response 
rate was 38% with 1 death during induction. Adverse events 
were mainly less than or equal to grade 2, including transient 
liver enzyme elevations, nausea, diarrhea, skin rash, muco-
sitis, and palmo-plantar erythrodysesthesias. A Children’s 
Oncology Group (COG) study (AAML0523) is underway to 
explore the safety and effecacy of this combination.
Safety and tolerability
Clofarabine is tolerated at 20 times higher doses in 
leukemia patients than in patients with solid tumors, where 
Table 4 Response to clofarabine in phase II trials in United States
 Responses/Total  (%)
Response ALL  AML
CR 7/61  (12%) 
CRp  5/61 (8%)  1/35 (3%)
PR  6/61 (10%)  8/35 (23%)
CR + CRp  12/61 (20%)  1/35 (3%)
CR + CRp + PR  18/61 (30%)  9/35 (26%)
Derived from data of Jeha et al (2006 and 2004).
Abbreviations: CR, complete remission; CRp, complete remission without full 
platelet recovery; PR, partial remission.Therapeutics and Clinical Risk Management 2008:4(2) 333
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myelosuppression is dose-limiting (Kantarjian et al 2003b). 
The dose-limiting toxicity in pediatric leukemia patients is 
hyperbilirubinemia and transient elevations in liver enzymes, 
which reversed by day 14, as well as grade 3 skin rash (Jeha 
et al 2004). Some patients experienced CNS irritability with 
the 1-hour infusion, which resolved when the clofarabine 
was given over 2 hours. Other adverse events greater than or 
equal to grade 3 which occurred in 10% or more of patients 
included febrile neutropenia, anorexia, hypotension, nausea, 
sepsis, and pleural effusion (Jeha et al 2006a, b). Drug-related 
fevers and skin rash generally responded to antihistamines 
and may require low-dose corticosteroids, once infection is 
excluded. Clofarabine administration has been associated 
with rapid decreases in blasts even in non-responders; this 
may be accompanied by tumor lysis syndrome or systemic 
inﬂ  ammatory response and capillary leak syndrome, with 
respiratory distress, fever, and hypotension. Cytokine-release 
like events may have contributed to a decline in cardiac func-
tion that was observed in several patients.
Drug interactions and concomitant 
medications
No clinical drug-drug interaction studies have been conducted 
to date. Clofarabine is primarily excreted by the kidneys, 
thus it may potentiate the toxicity of known nephrotoxic 
drugs, including aminoglycoside antibiotics. Tumor lysis 
and hyperuricemia may also contribute to renal toxicity. The 
concomitant use of medications known to induce hepatic 
toxicity should also be avoided, since hepato-biliary toxicities 
were observed in pediatric trials. In addition, patients taking 
medications known to affect blood pressure or cardiac func-
tion should be closely monitored during the administration of 
clofarabine, as symptoms of cytokine release and capillary 
leak syndrome, including hypotension, tachycardia, and 
pulmonary edema, have been reported in patients undergoing 
treatment with clofarabine (Clolar® package insert).
Dosage
The recommended dose and schedule of clofarabine as a 
single agent for pediatric patients is 52 mg/m2 administered 
by intravenous (IV) infusion over 2 hours daily for 5 con-
secutive days. The dosage is based on the patient’s BSA, 
calculated using the actual height and weight before the 
start of each cycle. Treatment cycles are repeated following 
blood count recovery or return to baseline organ function, 
approximately every 2–6 weeks (Clolar® package insert). 
To prevent drug incompatibilities, no other medications 
should be administered through the same intravenous line. 
Clofarabine should be administered along with IV infusion 
ﬂ  uids to reduce the effects of tumor lysis and other adverse 
events. Allopurinol may be administered prophylactically if 
hyperuricemia is expected. The use of prophylactic steroids 
(eg, 100 mg/m2 hydrocortisone on days 1 through 3) may 
be of beneﬁ  t in preventing signs or symptoms of systemic 
inﬂ  ammatory response syndrome (SIRS)/capillary leak syn-
drome. If signs or symptoms of SIRS or capillary leak occur 
(eg, hypotension), clofarabine should be discontinued and the 
use of steroids, diuretics, and albumin considered. According 
to the manufacturer, clofarabine can be re-instituted when the 
patient is stable and organ function has returned to baseline, 
generally with a 25% dose reduction.
Conclusions
Better use of existing drugs has dramatically improved 
survival rates for childhood acute leukemias over the past 
few decades. However, relapsed and refractory childhood 
leukemias remain a signiﬁ  cant therapeutic challenge. Relapse 
after multi-agent therapy may arise from mutations in shared 
cell-death pathways, rather than alterations in speciﬁ  c drug 
activation, drug elimination, or drug targets. In addition 
to resistant disease, heavily pretreated patients often have 
underlying infection and pre-existing organ dysfunction. New 
candidate agents need be evaluated in combination. Agents 
may have substantial single agent activity, yet contribute 
nothing in combination, eg, ifosfamide in rhabdomyosar-
coma (Miser et al 1987; Crist et al 2001). Conversely, an 
agent may have no single agent activity, yet still contribute 
in combination, eg, leukovorin in colon cancer (Iqbal and 
Lenz 2004).
Clofarabine is safe and active in both myeloid and 
lymphoid relapsed/refractory pediatric acute leukemias in 
single agent phase I and II trials. Myelosuppression was an 
acceptable effect in this population, and the neurotoxicity 
associated with previous generation nucleoside analogs 
was not observed with clofarabine. Responses in relapsed 
Table 5 Response to combination of clofarabine/cyclophosphamide/
etoposide in pediatric leukemia patients
 Responses/Total  (%) 
Response ALL  AML
CR 7/14  (50%) 
CRp  2/14 (8%)  3/3 (100%)
PR  
CR + CRp  9/ 14 (64%)  3/3 (100%)
Adapted from Hijaya et al 2007.
Abbreviations: CR, complete remission; CRp, complete remission without full 
platelet recovery; PR, partial remission.Therapeutics and Clinical Risk Management 2008:4(2) 334
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pediatric ALL were durable and allowed some patients to 
successfully proceed to transplantation. Clofarabine has 
been approved by the FDA for the treatment of pediatric 
patients with relapsed or refractory ALL after at least 
2 prior therapeutic regimens based on the induction of com-
plete responses. Over the past decade, clofarabine has been 
the only anti-cancer agent to receive primary indication for 
use in children.
Rational combinations of clofarabine with other active 
agents in refractory leukemias are currently under investi-
gation. The early results of the phase I study of clofarabine 
in combination with cyclophosphamide and etoposide 
in pediatric patients with relapsed or refractory ALL or 
AML indicate that this combination shows significant 
activity in children with both subtypes of refractory leu-
kemia and is well tolerated (Hijiya et al 2007). Pediatric 
studies of clofarabine in combination with cytarabine to 
enhance intracellular Ara-C triphosphate accumulation are 
also in progress. Such rationally designed combinations 
of clofarabine with standard agents may have a role in 
frontline therapy for newly diagnosed patients with higher 
risk disease. As of September, 2007 COG plans to study 
clofarabine-based combinations in a randomized phase III 
trial in patients with “very high risk” B-precursor ALL, 
ie, hypodiploidy, higher end-induction MRD, and/or 
induction failure. The proposed study tests a clofarabine 
blocks against the cyclophophamide/ara-c/thiopurine 
blocks that occupy 3 of the first 6 months of post-induction 
intensification. Plans in AML await completion of the 
current COG trials, AAML0523.
Disclosures
TMH has no conﬂ  icts of interest. PSG is on the speakers’ 
bureaus for Genzyme, Sanoﬁ  -Aventis, and Enzon.
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